Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

Folate-targeted dinitrophenyl hapten immunotherapy: effect of linker chemistry on antitumor activity and allergic potential.

Lu Y, You F, Vlahov I, Westrick E, Fan M, Low PS, Leamon CP.

Mol Pharm. 2007 Sep-Oct;4(5):695-706. Epub 2007 Sep 5.

PMID:
17784727
2.

Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors.

Lu Y, Low PS.

Cancer Immunol Immunother. 2002 May;51(3):153-62. Epub 2002 Mar 19.

PMID:
11941454
3.

Low-dose radiation potentiates the therapeutic efficacy of folate receptor-targeted hapten therapy.

Sega EI, Lu Y, Ringor M, Leamon CP, Low PS.

Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):559-66. doi: 10.1016/j.ijrobp.2008.02.010. Epub 2008 Apr 12.

PMID:
18411004
4.

Preclinical pharmacokinetics, tissue distribution, and antitumor activity of a folate-hapten conjugate-targeted immunotherapy in hapten-immunized mice.

Lu Y, Xu LC, Parker N, Westrick E, Reddy JA, Vetzel M, Low PS, Leamon CP.

Mol Cancer Ther. 2006 Dec;5(12):3258-67.

5.

Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue.

Leamon CP, Reddy JA, Vetzel M, Dorton R, Westrick E, Parker N, Wang Y, Vlahov I.

Cancer Res. 2008 Dec 1;68(23):9839-44. doi: 10.1158/0008-5472.CAN-08-2341.

6.

Folate-targeted hapten immunotherapy of adjuvant-induced arthritis: comparison of hapten potencies.

Yi YS, Ayala-López W, Kularatne SA, Low PS.

Mol Pharm. 2009 Jul-Aug;6(4):1228-36. doi: 10.1021/mp900070b.

PMID:
19374407
7.

Strategy to prevent drug-related hypersensitivity in folate-targeted hapten immunotherapy of cancer.

Lu Y, Klein PJ, Westrick E, Xu LC, Santhapuram HK, Bloomfield A, Howard SJ, Vlahov IR, Ellis PR, Low PS, Leamon CP.

AAPS J. 2009 Sep;11(3):628-38. doi: 10.1208/s12248-009-9139-7.

8.

Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential.

Lu Y, Sega E, Leamon CP, Low PS.

Adv Drug Deliv Rev. 2004 Apr 29;56(8):1161-76. Review.

PMID:
15094213
9.

Evaluation of an in vitro method for the measurement of specific IgE antibody responses: the rat basophilic leukemia (RBL) cell assay.

Dearman RJ, Skinner RA, Deakin N, Shaw D, Kimber I.

Toxicology. 2005 Jan 15;206(2):195-205.

PMID:
15588913
10.

Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate.

Reddy JA, Westrick E, Santhapuram HK, Howard SJ, Miller ML, Vetzel M, Vlahov I, Chari RV, Goldmacher VS, Leamon CP.

Cancer Res. 2007 Jul 1;67(13):6376-82.

11.

Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug.

Lu JY, Lowe DA, Kennedy MD, Low PS.

J Drug Target. 1999;7(1):43-53.

PMID:
10614814
13.
14.

Targeted drug delivery via folate receptors.

Zhao X, Li H, Lee RJ.

Expert Opin Drug Deliv. 2008 Mar;5(3):309-19. doi: 10.1517/17425247.5.3.309 . Review.

PMID:
18318652
15.

Targeted cancer therapy: conferring specificity to cytotoxic drugs.

Chari RV.

Acc Chem Res. 2008 Jan;41(1):98-107. Epub 2007 Aug 18. Review.

PMID:
17705444
17.

Impact of high and low folate diets on tissue folate receptor levels and antitumor responses toward folate-drug conjugates.

Leamon CP, Reddy JA, Dorton R, Bloomfield A, Emsweller K, Parker N, Westrick E.

J Pharmacol Exp Ther. 2008 Dec;327(3):918-25. doi: 10.1124/jpet.108.143206. Epub 2008 Sep 12.

18.

Folate-targeted immunotherapy effectively treats established adjuvant and collagen-induced arthritis.

Paulos CM, Varghese B, Widmer WR, Breur GJ, Vlashi E, Low PS.

Arthritis Res Ther. 2006;8(3):R77. Epub 2006 Apr 28.

19.

Folate receptor specific anti-tumor activity of folate-mitomycin conjugates.

Reddy JA, Westrick E, Vlahov I, Howard SJ, Santhapuram HK, Leamon CP.

Cancer Chemother Pharmacol. 2006 Aug;58(2):229-36. Epub 2005 Dec 6.

PMID:
16331500
20.

Effect on tolerance induction of the mode of attachment of the hapten the carrier.

Paley RS, Leskowitz S, Borel Y.

J Immunol. 1975 Nov;115(5):1409-13.

PMID:
1100732
Items per page

Supplemental Content

Write to the Help Desk